In this video, Fool.com health care analysts David Williamson and Max Macaluso discuss Gilead, Amarin, and Cyclacel's intraday pops of more than 5%. One reported excellent earnings, another is subject to buyout rumors, and a third continues its recent winning streak. Watch and find out what this means for these stocks, their competitors, and investors.
S&P 500
$5,919.54
+0.0%
+$2.61
DJI
$42,357.17
+0.1%
+$34.42
NASDAQ
$19,103.14
-0.0%
-$9.18
Bitcoin
$103,639.00
+1.8%
+$1,818.93
AAPL
$210.11
-0.6%
-$1.34
AMZN
$204.88
-0.1%
-$0.29
GOOG
$167.74
+1.4%
+$2.34
META
$630.89
-2.0%
-$12.99
MSFT
$449.41
-0.8%
-$3.72
NVDA
$134.54
-0.2%
-$0.29
TSLA
$346.28
+1.0%
+$3.46
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.